Promises from trametinib in RAF active tumors

N Engl J Med. 2012 Jul 12;367(2):171-2. doi: 10.1056/NEJMe1205654. Epub 2012 Jun 4.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • MAP Kinase Kinase 1 / antagonists & inhibitors*
  • MAP Kinase Kinase 2 / antagonists & inhibitors*
  • Male
  • Melanoma / drug therapy*
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Pyridones / therapeutic use*
  • Pyrimidinones / therapeutic use*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • trametinib
  • MAP2K2 protein, human
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • MAP Kinase Kinase 1
  • MAP Kinase Kinase 2
  • MAP2K1 protein, human